Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sparrow HLC
Portland, Oregon, United Statescitynews-messinatoday.stgy.ovh ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Sparrow Pharmaceuticals' lead candidate, clofutriben (SPI‑62), a potent and selective HSD1 inhibitor, has entered multiple Phase 2 clinical trials for Cushing’s syndrome, autonomous cortisol secretion (ACS), and polymyalgia rheumatica. Initial data from these studies are expected in 2024. The company collaborates with leading academic institutions on investigator-led studies.
- Therapeutic areas
- EndocrinologyRheumatologyImmunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
University of Oxford: Academic collaboration for DC-MACS study in ACSUniversity of Sheffield: Academic collaboration for DC-MACS study in ACS
Beyond the preview
Go deeper on Sparrow HLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sparrow HLC.